vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Rimini Street, Inc. (RMNI). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $105.5M, roughly 1.7× Rimini Street, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 1.3%, a 12.1% gap on every dollar of revenue. On growth, Rimini Street, Inc. posted the faster year-over-year revenue change (1.2% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 1.1%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
AMPH vs RMNI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $105.5M |
| Net Profit | $24.4M | $1.4M |
| Gross Margin | 46.8% | 59.0% |
| Operating Margin | 19.4% | 4.6% |
| Net Margin | 13.3% | 1.3% |
| Revenue YoY | -1.8% | 1.2% |
| Net Profit YoY | -35.7% | -59.4% |
| EPS (diluted) | $0.51 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $105.5M | ||
| Q4 25 | $183.1M | $109.8M | ||
| Q3 25 | $191.8M | $103.4M | ||
| Q2 25 | $174.4M | $104.1M | ||
| Q1 25 | $170.5M | $104.2M | ||
| Q4 24 | $186.5M | $114.2M | ||
| Q3 24 | $191.2M | $104.7M | ||
| Q2 24 | $182.4M | $103.1M |
| Q1 26 | — | $1.4M | ||
| Q4 25 | $24.4M | $724.0K | ||
| Q3 25 | $17.4M | $2.8M | ||
| Q2 25 | $31.0M | $30.3M | ||
| Q1 25 | $25.3M | $3.4M | ||
| Q4 24 | $38.0M | $6.7M | ||
| Q3 24 | $40.4M | $-43.1M | ||
| Q2 24 | $37.9M | $-1.1M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | 46.8% | 60.4% | ||
| Q3 25 | 51.4% | 59.9% | ||
| Q2 25 | 49.6% | 60.4% | ||
| Q1 25 | 50.0% | 61.0% | ||
| Q4 24 | 46.5% | 63.7% | ||
| Q3 24 | 53.3% | 60.7% | ||
| Q2 24 | 52.2% | 59.1% |
| Q1 26 | — | 4.6% | ||
| Q4 25 | 19.4% | 4.5% | ||
| Q3 25 | 13.2% | 4.2% | ||
| Q2 25 | 24.2% | 39.6% | ||
| Q1 25 | 21.9% | 9.0% | ||
| Q4 24 | 24.2% | 13.0% | ||
| Q3 24 | 29.8% | -47.4% | ||
| Q2 24 | 30.3% | -0.8% |
| Q1 26 | — | 1.3% | ||
| Q4 25 | 13.3% | 0.7% | ||
| Q3 25 | 9.0% | 2.7% | ||
| Q2 25 | 17.8% | 29.1% | ||
| Q1 25 | 14.8% | 3.2% | ||
| Q4 24 | 20.4% | 5.8% | ||
| Q3 24 | 21.1% | -41.2% | ||
| Q2 24 | 20.8% | -1.1% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $0.51 | $0.00 | ||
| Q3 25 | $0.37 | $0.03 | ||
| Q2 25 | $0.64 | $0.32 | ||
| Q1 25 | $0.51 | $0.04 | ||
| Q4 24 | $0.74 | $0.07 | ||
| Q3 24 | $0.78 | $-0.47 | ||
| Q2 24 | $0.73 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $132.2M |
| Total DebtLower is stronger | $608.7M | $56.4M |
| Stockholders' EquityBook value | $788.8M | — |
| Total Assets | $1.6B | $397.1M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $132.2M | ||
| Q4 25 | $282.8M | $120.0M | ||
| Q3 25 | $276.2M | $108.7M | ||
| Q2 25 | $231.8M | $101.3M | ||
| Q1 25 | $236.9M | $122.6M | ||
| Q4 24 | $221.6M | $88.8M | ||
| Q3 24 | $250.5M | $119.5M | ||
| Q2 24 | $217.8M | $134.2M |
| Q1 26 | — | $56.4M | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $788.8M | $-27.0M | ||
| Q3 25 | $776.7M | $-27.3M | ||
| Q2 25 | $757.5M | $-29.0M | ||
| Q1 25 | $751.3M | $-63.7M | ||
| Q4 24 | $732.3M | $-69.4M | ||
| Q3 24 | $727.7M | $-76.8M | ||
| Q2 24 | $713.3M | $-36.1M |
| Q1 26 | — | $397.1M | ||
| Q4 25 | $1.6B | $423.1M | ||
| Q3 25 | $1.7B | $352.9M | ||
| Q2 25 | $1.6B | $397.5M | ||
| Q1 25 | $1.6B | $343.0M | ||
| Q4 24 | $1.6B | $369.1M | ||
| Q3 24 | $1.5B | $343.8M | ||
| Q2 24 | $1.5B | $367.4M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $19.6M | ||
| Q3 25 | $52.6M | $24.7M | ||
| Q2 25 | $35.6M | $-17.8M | ||
| Q1 25 | $35.1M | $33.7M | ||
| Q4 24 | $29.0M | $-37.7M | ||
| Q3 24 | $60.0M | $-18.5M | ||
| Q2 24 | $69.1M | $6.3M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $18.9M | ||
| Q3 25 | $47.2M | $23.5M | ||
| Q2 25 | $25.0M | $-19.5M | ||
| Q1 25 | $24.4M | $32.8M | ||
| Q4 24 | $16.6M | $-38.4M | ||
| Q3 24 | $46.2M | $-19.2M | ||
| Q2 24 | $63.1M | $5.4M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 17.2% | ||
| Q3 25 | 24.6% | 22.7% | ||
| Q2 25 | 14.3% | -18.8% | ||
| Q1 25 | 14.3% | 31.5% | ||
| Q4 24 | 8.9% | -33.6% | ||
| Q3 24 | 24.1% | -18.3% | ||
| Q2 24 | 34.6% | 5.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.6% | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 6.1% | 1.7% | ||
| Q1 25 | 6.3% | 0.9% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 27.02× | ||
| Q3 25 | 3.03× | 8.94× | ||
| Q2 25 | 1.15× | -0.59× | ||
| Q1 25 | 1.39× | 10.06× | ||
| Q4 24 | 0.76× | -5.66× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RMNI
Segment breakdown not available.
